<DOC>
	<DOC>NCT01722409</DOC>
	<brief_summary>The investigators designed a double-blind, randomized placebo-controlled study to determine the effects of dexmedetomidine on the recovery characteristics of patients who were scheduled to undergo endovascular coil embolization.</brief_summary>
	<brief_title>A Better Choice for Patients Undergoing Endovascular Coil Embolization</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1865 years old ASA I or ASA II patients undergoing ECE treatment for intracranial aneurysms were included. Patients were excluded based on the following parameters: older than 65 yrs, a history of mental illness, recent use of sedatives or analgesics and with sensation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>dexmedetomidine, endovascular coil embolization</keyword>
</DOC>